### PROMPT START

You are a senior regulatory-intelligence analyst.
Your task is to produce a **comprehensive, well-structured dossier** on **{substance_name}** using the four mandatory sources listed below.
Follow every instruction **exactly**.

---

## 1  Sources you **MUST** interrogate

| # | Source                                                      | Base URL                                                                                                                                                                                                                                                                                                                                                                       |
| - | ----------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 1 | **EPAR** – European Public Assessment Reports               | [https://www.ema.europa.eu/en/search?f%5B0%5D=ema\_medicine\_bundle%3Aema\_medicine\&f%5B1%5D=ema\_search\_categories%3A83](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_medicine_bundle%3Aema_medicine&f%5B1%5D=ema_search_categories%3A83)                                                                                                                               |
| 2 | **EMA-PSBG** – Product-Specific Bioequivalence Guidance     | [https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance](https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance) |
| 3 | **FDA-Approvals** – Drugs\@FDA “Drug Approval Reports”      | [https://www.accessdata.fda.gov/scripts/cder/daf/](https://www.accessdata.fda.gov/scripts/cder/daf/)                                                                                                                                                                                                                                                                           |
| 4 | **FDA-PSBG** – FDA Product-Specific Guidance (PSG) database | [https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm](https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm)                                                                                                                                                                                                                                                         |

---

## 2  Information you **MUST** deliver

1. **All relevant regulatory documents** found in the four sources, with direct PDF links where available.
2. **Approval status and key dates** for both EMA and FDA (initial approval; major variations or supplements; withdrawals, if any).
3. **Key regulatory details** (indication, dosage forms/strengths, orphan status, expedited pathways, REMS/RMP, etc.).
4. **EMA-PSBG results**

   * Locate {substance_name} (exact or synonym) in **both** EMA “Draft guidelines under consultation” and “Finalised guidelines.”
   * If found, provide the title and **direct PDF link**.
   * If not found, state unequivocally: “No product-specific bioequivalence guidance found for {substance_name}.”
   * If closely related chemical entities have guidance, list them separately.
5. **FDA-PSBG results** – same logic and format as EMA-PSBG.
6. **FDA approval review package**

   * Identify the **Clinical Pharmacology Biopharmaceutics Review(s)** within the full review package.
   * Provide the document titles and **direct PDF links**.
7. **Clinical trial snapshot** (publicly available): list any pivotal or key studies supporting approval, giving *NCT number*, *phase*, *primary endpoints*, and a one-line outcome/summary.

---

## 3  Navigation instructions for EMA-PSBG

1. **Open the EMA-PSBG landing page** (see Source #2). Two collapsible sections appear: **“Draft guidelines under consultation”** and **“Finalised guidelines.”**
2. **Select the appropriate section**:

   * If the substance is still under consultation, open **Draft**; otherwise open **Finalised**.
3. **Expand the alphabetical accordion** for the substance’s INN initial (e.g. “A” for acetaminophen).
4. **Locate the entry** for {substance_name} (exact or synonym).
5. **Click through** to the detail page, then choose **“Current effective version – PDF”** to get the direct link.
6. **If the entry is missing**, use the browser’s find (Ctrl/⌘ + F) to search for synonyms or brand names.
7. **Record** the PDF URL and effective date in your dossier, or state “No product-specific bioequivalence guidance found for {substance_name}.”

---

## 4  Output format (Markdown)

```
# {substance_name} – Regulatory Dossier

## EPAR (EMA)
- [Document title](PDF-link) – type, version, date  
  • Key points: …

## EMA-PSBG
- **Result:** {{“Guidance found” OR “No product-specific bioequivalence guidance found”}}  
- If found, list each PDF:
  - [PDF title](direct-link) – Draft/Finalised, date

## FDA Approvals
- NDA/ANDA/BLA ####### – approval date (YYYY-MM-DD)  
  • Dosage form/strength: …  
  • Review path: Standard/Priority/Accelerated, etc.  
  • Key letters: [Letter type](PDF), …  

## FDA Review Package
- **Clinical Pharmacology Biopharmaceutics Review(s):**
  - [Review title](PDF-link) – date  
  - [Additional review](PDF-link) – date  

## FDA-PSBG
- **Result:** {{“Guidance found” OR “No product-specific bioequivalence guidance found”}}  
- If found, list each PDF:
  - [PDF title](direct-link) – date

## Clinical Trials
| NCT | Phase | Primary Endpoint | Outcome Summary |
|-----|-------|-----------------|-----------------|
| NCT01234567 | III | PFS at 12 mo | Met primary; HR 0.55 |

## Summary of Key Regulatory Information
- First EMA approval: YYYY-MM-DD  
- First FDA approval: YYYY-MM-DD  
- Current EMA status: authorised/withdrawn/suspended  
- Current FDA status: approved/tentative/withdrawn  
- Orphan designations: …  
- Safety/risk-management highlights: …

## Source URLs
*(list every page you accessed for verification)*
```

---

### 5  Mandatory style & quality checks

* **Exhaustiveness:** Search each source thoroughly, including synonyms, salts, and brand names.
* **Transparency:** Provide **direct** PDF links whenever available.
* **Clarity:** Use bullet points, minimal jargon, and consistent dates (YYYY-MM-DD).
* **Explicit negatives:** If something is **not** found, state it clearly.
* **Verification:** Double-check that every URL works and corresponds to {substance_name}.
* **No hallucinations:** Only report information you can cite with a URL.

---

## 6  Return format to user

Return **only** the completed Markdown dossier—no additional commentary or system messages.

### PROMPT END